Focused Pharmacogenomics Panel, Varies
Use
This panel provides a comprehensive analysis for multiple genes with strong drug phenotype associations. It assists in preemptive or reactive genotyping of patients for pharmacogenomic purposes, providing an assessment for genes with strong drug-gene associations, and aiding in the management of patients with complex medication regimens.
Special Instructions
New York Clients should have informed consent documented. For specimens from patients with hematopoietic stem cell transplants, additional communications may be needed to ensure accurate testing.
Limitations
This test is not designed to provide specific dosing recommendations and is to be used as an aid to clinical decision making only. Results should be used in conjunction with other clinical and laboratory data. Specimens from patients who have received non-leukocyte reduced blood transfusions or allogeneic hematopoietic stem cell transplantation may contain donor DNA that could interfere with results.
New York Approved
Methodology
PCR-based (RT-PCR)
Biomarkers
LOINC Codes
- 82118-1
- 72884-0
- 94254-0
- 57132-3
- 79714-2
- 104667-1
- 46724-1
- 79716-7
- 104668-9
- 40425-1
- 79715-9
- 104669-7
- 81139-8
- 81145-5
- 81140-6
- 79717-5
- 93412-5
- 79722-5
- 50722-8
- 54451-0
- 93197-2
- 93198-0
- 69047-9
- 48767-8
- 62364-5
- 18771-6
- 85069-3
Result Turnaround Time
3-14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
Not provided
Container
Lavender top (EDTA)
Collection Instructions
Invert several times to mix blood. Send whole blood specimen in original tube. Do not aliquot.
Patient Preparation
A previous hematopoietic stem cell transplant from an allogenic donor will interfere with testing.
Causes for Rejection
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |
| Refrigerated | 4 days |
| Frozen | 4 days |